- Home
- SAFE vs SYRE Comparison
SAFE vs SYRE Comparison
Compare SAFE & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAFE
- SYRE
- Stock Information
- Founded
- SAFE 2016
- SYRE 2013
- Country
- SAFE United States
- SYRE United States
- Employees
- SAFE N/A
- SYRE N/A
- Industry
- SAFE Real Estate Investment Trusts
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- SAFE Real Estate
- SYRE Health Care
- Exchange
- SAFE Nasdaq
- SYRE Nasdaq
- Market Cap
- SAFE 1.2B
- SYRE 1.3B
- IPO Year
- SAFE 2017
- SYRE 2016
- Fundamental
- Price
- SAFE $16.83
- SYRE $21.29
- Analyst Decision
- SAFE Buy
- SYRE Strong Buy
- Analyst Count
- SAFE 9
- SYRE 8
- Target Price
- SAFE $25.22
- SYRE $51.50
- AVG Volume (30 Days)
- SAFE 421.1K
- SYRE 574.3K
- Earning Date
- SAFE 02-05-2025
- SYRE 03-03-2025
- Dividend Yield
- SAFE 4.21%
- SYRE N/A
- EPS Growth
- SAFE N/A
- SYRE N/A
- EPS
- SAFE 1.48
- SYRE N/A
- Revenue
- SAFE $388,662,000.00
- SYRE N/A
- Revenue This Year
- SAFE N/A
- SYRE $168.62
- Revenue Next Year
- SAFE $8.16
- SYRE $47.61
- P/E Ratio
- SAFE $11.37
- SYRE N/A
- Revenue Growth
- SAFE 3.15
- SYRE N/A
- 52 Week Low
- SAFE $15.55
- SYRE $20.13
- 52 Week High
- SAFE $28.80
- SYRE $47.97
- Technical
- Relative Strength Index (RSI)
- SAFE 46.13
- SYRE 40.66
- Support Level
- SAFE $16.63
- SYRE $21.61
- Resistance Level
- SAFE $17.85
- SYRE $23.04
- Average True Range (ATR)
- SAFE 0.58
- SYRE 1.43
- MACD
- SAFE 0.07
- SYRE -0.03
- Stochastic Oscillator
- SAFE 50.47
- SYRE 22.03
About SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.